Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status approved; investigational
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 0781-9253; 14096-121; 81955-0012; 16729-306; 55150-393; 63323-771; 68001-527; 69097-368; 69097-805; 71288-153; 72485-201; 65129-1222; 68554-0104; 72606-558; 53183-4011; 43598-678; 59572-102; 51916-350; 83137-0006; 16714-927; 43817-906; 59572-730; 68001-504; 71288-115; 63660-0010; 0781-3253; 42385-312; 66529-0013; 54893-0029; 82920-015; 68001-313; 42385-719; 43598-305; 16714-578; 51991-797; 64679-096; 70121-1237; 63592-1800; 0143-9606; 43598-143; 43598-465; 59572-740
UNII M801H13NRU
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemodynamic instability24.03.02.0060.000168%Not Available
Gastrointestinal hypomotility07.02.02.0050.000112%Not Available
Catheter site erythema23.03.06.014; 12.07.02.003; 08.02.02.0030.000246%Not Available
Lymphatic disorder01.09.01.003--Not Available
Large intestinal haemorrhage24.07.02.026; 07.12.03.0030.000168%
Drug tolerance decreased08.06.01.0240.000112%Not Available
Perirectal abscess11.01.07.005; 07.19.04.001--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Leukaemia cutis16.01.03.002; 01.10.03.002--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000336%Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.000504%Not Available
Injection site swelling12.07.03.018; 08.02.03.017--Not Available
Cerebral haematoma17.08.01.014; 24.07.04.0060.000112%Not Available
Nodule08.03.05.002--Not Available
Klebsiella sepsis11.02.03.002--Not Available
Haemorrhoidal haemorrhage24.10.02.001; 07.15.03.002--
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Haemorrhage24.07.01.0020.002742%Not Available
Haemorrhage urinary tract24.07.01.007; 20.02.03.0050.000168%Not Available
Faecaloma07.01.03.0040.000504%Not Available
Pulmonary mass22.02.07.0040.000112%Not Available
Intra-abdominal haematoma24.07.02.034; 07.12.02.0050.000112%Not Available
Pneumatosis intestinalis07.11.01.0430.000280%Not Available
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.000168%Not Available
Staphylococcal infection11.02.05.002--Not Available
Metabolic disorder14.11.01.0010.000168%Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.000504%Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.0300.000112%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000694%Not Available
Angiopathy24.03.02.007--Not Available
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 19 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene